Guidelines adherence and hypertension control in an outpatient cardiology clinic in Malaysia

Tropical Journal of Pharmaceutical Research

Volumn 11, Issue 4, 2012, Pages 665-672

  Ahmad, Nafees ^a   Hassan, Yahaya ^b   Tangiisuran, Balamurugan ^a   Meng, Ong Loke ^c   Aziz, Noorizan Abd ^b   Khan, Amer Hayat ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c One Stop Centre Clinical Research Centre Ministry of Health ^*  (Malaysia)

Author keywords

Adherence; Cardiology; Diabetes; Guidelines; Hypertension control

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; ASTHMA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHINESE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNICITY; FAMILY HISTORY; FEMALE; GOUT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INDIAN; MAJOR CLINICAL STUDY; MALAY; MALAYSIA; MALE; MONOTHERAPY; OUTPATIENT DEPARTMENT; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; PROTEINURIA;

EID: 84865681835     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v11i4.19     Document Type: Article

References (23)

1. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens 2003;21(6):1055-1076
2. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005;45(6):813-827.
3. rded. 2008. MOH/P/PAK/ 156.08 (GU).
4. Asch SM, Kerr EA, Lapuerta P, Law A, McGlynn EA. A new approach for measuring quality of care for women with hypertension. Arch Intern Med 2001;161(10):1329-1335
5. Borzecki AM, Oliveria SA, Berlowitz DR. Barriers to hypertension control. Am Heart J 2005;149(5):785-794.
6. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med 2001;135(9):825-834
7. Rampal L, Rampal S, Azhar MZ, Rahman AR. Prevalence, awareness, treatment and control of hypertension in Malaysia: A national study of 16,440 subjects. Public Health 2008;122(1):11-18.
8. Western Pacific Country Health Information Profiles: 2007 Revision: World Health Organization Western Pacific Region.[cited 2011 June 28]. Available from http://www.wpro.who.int/internet/files/hin/chips 2007.pdf
9. Kotrlik JW, Williams HA. The Incorporation of Effect Size in Information Technology, Learning, and Performance Research. Information Technology, Learning, and Performance Journal 2003;21(1):1-7.
10. Mitchell ML, Jolley JM. Research design explained. Wadsworth Pub Co; 2009. 293 p.
11. Jami P, Smith P, Moningi S, Moningi V, Martin SA, Rosencrance G, et al. Compliance with Joint National Committee 7 guidelines in hypertension management in a teaching institution. Am J Med Qual 2007;22(4):251-258
12. Chan GC. Type 2 diabetes mellitus with hypertension at primary healthcare level in Malaysia: are they managed according to guidelines? Singapore Med J 2005;46(3):127-131.
13. Odili VU, Oghagbon EK, Ugwa NA, Ochei UM, Aghomo OE. Adherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria. Trop J Pharm Res 2008;7(2):945-952.
14. Houlihan SJ, Simpson SH, Cave AJ, Flook NW, Hurlburt ME, Lord CJ, et al. Hypertension treatment and control rates: Chart review in an academic family medicine clinic. Can Fam Physician 2009;55(7):735-741
15. Piette JD, Richardson C, Valenstein M. Addressing the needs of patients with multiple chronic illnesses: the case of diabetes and depression. Am J Manage Care 2004;10(2; Pt 2):152-162.
16. Ardery G, Carter BL, Milchak JL, Bergus GR, Dawson JD, James PA, et al. Explicit and implicit evaluation of physician adherence to hypertension guidelines. J Clin Hypertens 2007;9(2):113-119.
17. Oteh M, Azarisman SMS, Azreen SA, Jamaluddin AR, Aszrin A, Ting CK, et al. Institutional hypertension control in Malaysia: a multicenter study focusing on gender and cardiovascular risk factor profile difference. Hypertens Res 2011;34(3):319-324.
18. Yokokawa H, Goto A, Sanada H, Watanabe T, Yasumura S. Gaps Between Hypertension Treatment Guidelines and Clinical Practice in Japan: Baseline Survey Results From Fukushima Research of Hypertension (FRESH). J Clin Hypertens 2009;11(6):333-341.
19. Street Jr RL, Gordon HS, Ward MM, Krupat E, Kravitz RL. Patient participation in medical consultations: why some patients are more involved than others. Med Care 2005:960-969.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators. NEJM 2000;342(3):145-153.
21. Mann JFE. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355(9200):253-259.
22. Singer GM, Izhar M, Black HR. Guidelines for Hypertension: Are Quality Assurance Measures on Target? Hypertension 2004;43(2):198-202
23. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4(6):393-404.